AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Delcath Systems Inc (NASDAQ:DCTH)
11.87 USD
+0.530 4.674%Sponsored Reports
Loading...
| Previous Close (in USD) | 11.34 |
|---|---|
| Change | +0.530 4.674% |
| 52 W H/L (in USD) | 8.500/2.250 |
| EBITDA (in USD) | -38.054M |
| PE Ratio | -- |
| Volume | 1199669 |
| Diluted Eps TTM | -2.48 |
| Total Assets (in USD) | 38.613M |
|---|---|
| Total Liabilities (in USD) | 22.836M |
| Revenue TTM (in USD) | 2.065M |
| Cash (in USD) | 12.696M |
| Market Cap (in USD) | 204.226 M |
| Revenue Per Share TTM | 0.127 |
| Gross Profit TTM (in USD) | 2.033M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Employees: 76
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Gerard J. Michel MBA, MS | CEO & Director | 1963 |
| 2. | Mr. John Purpura M.S. | Chief Operating Officer | 1961 |
| 3. | Dr. Johnny John M.D. | Sr. VP Clinical Devel. & Medical Affairs | 1964 |
| 4. | Mr. Anthony C. Dias | VP of Fin. | 1967 |
| 5. | Mr. David Hoffman | Gen. Counsel, Corp. Sec. & Chief Compliance Officer | NA |
| 6. | Mr. Robin Wagge | Sr. VP of Rubenstein Associates | NA |
| 7. | Mr. Kevin Muir | VP of Commercial Operations | NA |
| 8. | Dr. Johnny John M.D. | Senior Vice President of Clinical Operations & Medical Affairs | 1965 |
| 9. | Ms. Sandra Pennell | Senior VP of Finance and Principal Financial & Accounting Officer | 1979 |
| 10. | Dr. Martha S. Rook Ph.D. | Chief Operating Officer | 1972 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
+0.010 0.008% | 132.02 | 37.150 | 23.148 | 4.666 | 4.975 | 4.878 | 19.381 |
|
SYK
Stryker Corporation |
+2.000 0.514% | 387.92 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
-0.190 0.211% | 89.75 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
+1.130 1.095% | 102.66 | 68.170 | 24.570 | 5.855 | 4.265 | 6.462 | 26.799 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -36.508M | -25.649M | -24.156M | -8.879M | -19.222M |
| Minority Interest | - | - | - | - | - |
| Net Income | -39.163M | -26.757M | -24.485M | -13.627M | -19.222M |
| Selling General Administrative | 17.303M | 13.637M | 11.108M | 11.279M | 9.819M |
| Gross Profit | 2.033M | 2.884M | 1.006M | 0.861M | 2.398M |
| Reconciled Depreciation | 0.132M | 0.146M | 0.192M | 1.789M | 0.444M |
| Ebit | -33.853M | -24.531M | -21.303M | -19.908M | -27.02M |
| Ebitda | -33.691M | -24.463M | -20.957M | -18.117M | -26.576M |
| Depreciation And Amortization | 0.162M | 0.068M | 0.346M | 1.791M | 0.444M |
| Operating Income | -33.853M | -24.531M | -21.303M | -19.908M | -27.071M |
| Other Operating Expenses | 36.572M | 28.086M | 22.949M | 21.488M | 30.478M |
| Interest Expense | 2.685M | 1.186M | 0.175M | 4.746M | 7.959M |
| Tax Provision | - | - | - | - | - |
| Interest Income | - | - | - | - | - |
| Net Interest Income | -2.685M | -1.186M | -0.175M | -4.746M | -7.959M |
| Income Tax Expense | 2.655M | 1.108M | 0.329M | 4.748M | 15.808M |
| Total Revenue | 2.719M | 3.555M | 1.646M | 1.58M | 3.407M |
| Total Operating Expenses | 35.886M | 27.415M | 22.309M | 20.769M | 29.469M |
| Cost Of Revenue | 0.686M | 0.671M | 0.64M | 0.719M | 1.009M |
| Total Other Income Expense Net | -2.655M | -1.118M | -2.853M | 11.029M | 15.808M |
| Net Income From Continuing Ops | -36.508M | -25.649M | -24.156M | -8.879M | -19.222M |
| Net Income Applicable To Common Shares | -36.508M | -25.649M | -24.211M | -8.879M | -19.222M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 38.613M | 17.862M | 33.124M | 34.635M | 14.212M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 0.94M | 0.095M | 2.743M | 0.328M | 0.363M |
| Total Liab | 22.836M | 23.721M | 21.172M | 12.557M | 20.569M |
| Total Stockholder Equity | 15.777M | -5.859M | 11.952M | 22.078M | -6.357M |
| Other Current Liab | 5.249M | 4.685M | 4.109M | 5.241M | 3.368M |
| Common Stock | 0.228M | 0.1M | 0.079M | 0.06M | 0.001M |
| Capital Stock | 0.228M | 0.1M | 0.079M | 0.06M | 0.001M |
| Retained Earnings | -505.162M | -457.484M | -420.976M | -395.327M | -371.171M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | - | - | 0.946M | - |
| Cash | 12.696M | 7.671M | 22.802M | 28.575M | 10.002M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 16.448M | 14.735M | 5.954M | 10.035M | 15.512M |
| Current Deferred Revenue | - | - | 0.17M | 0.525M | 6.947M |
| Net Debt | -1.669M | 8.203M | -6.547M | -25.63M | -7.141M |
| Short Term Debt | 10.187M | 8.032M | 1.037M | 2.495M | 0.664M |
| Short Long Term Debt | 10.15M | 7.846M | 0.621M | 2M | - |
| Short Long Term Debt Total | 11.027M | 15.874M | 16.255M | 2.945M | 2.861M |
| Other Stockholder Equity | 515.028M | 451.608M | 432.831M | 417.449M | 364.785M |
| Property Plant Equipment | - | 1.422M | 1.972M | 2.297M | 1.595M |
| Total Current Assets | 37.158M | 16.155M | 31.152M | 32.338M | 12.617M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 19.808M | - | - | - | - |
| Net Receivables | 0.392M | 0.366M | 0.044M | 0.057M | 0.052M |
| Long Term Debt | - | 7.842M | 15.011M | - | 2M |
| Inventory | 3.322M | 1.998M | 1.412M | 0.855M | 0.654M |
| Accounts Payable | 1.012M | 2.018M | 0.638M | 1.774M | 4.533M |
| Accumulated Other Comprehensive Income | 0.135M | -0.083M | 0.018M | -0.104M | 0.028M |
| Non Currrent Assets Other | -0M | 0.285M | - | - | - |
| Non Current Assets Total | 1.455M | 1.707M | 1.972M | 2.297M | 1.595M |
| Capital Lease Obligations | 0.037M | 0.186M | 0.623M | 0.945M | 0.861M |
| Long Term Debt Total | - | 7.842M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.209M | -0.143M | -0.782M | -0.024M | -0.076M |
| Total Cashflows From Investing Activities | -0.209M | -0.143M | -0.782M | -0.024M | -0.076M |
| Total Cash From Financing Activities | 10.143M | 20.822M | 42.355M | 30.305M | 13.236M |
| Net Income | -36.508M | -25.649M | -24.156M | -8.879M | -19.222M |
| Change In Cash | -15.131M | -1.803M | 18.573M | 6.605M | -1.746M |
| Begin Period Cash Flow | 26.953M | 28.756M | 10.183M | 3.578M | 5.324M |
| End Period Cash Flow | 11.822M | 26.953M | 28.756M | 10.183M | 3.578M |
| Total Cash From Operating Activities | -24.95M | -22.604M | -22.868M | -23.69M | -14.732M |
| Depreciation | 0.132M | 0.146M | 0.192M | 1.789M | 0.444M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -0.587M | -0.557M | -0.201M | 0.204M | 0.385M |
| Sale Purchase Of Stock | 10.857M | - | - | - | 0M |
| Other Cashflows From Financing Activities | -0.209M | 20.822M | 2.617M | 3.869M | 7.189M |
| Capital Expenditures | 0.209M | 0.143M | 0.782M | 0.024M | 0.076M |
| Change In Working Capital | 2.114M | -5.764M | -5.806M | -7.103M | 11.772M |
| Other Non Cash Items | 1.371M | 0.831M | 0.159M | 6.004M | 7.973M |
| Free Cash Flow | -25.159M | -22.747M | -23.65M | -23.714M | -14.808M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 565773 |
| 2. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 296042 |
| 3. | Fidelity Extended Market Index | 1 year ago | 130618 |
| 4. | BlackRock Extended Equity Market K | 1 year ago | 55739 |
| 5. | Fidelity Total Market Index | 1 year ago | 33339 |
| 6. | BlackRock Extended Mkt Composite | 1 year ago | 26646 |
| 7. | iShares Micro-Cap ETF | 1 year ago | 24291 |
| 8. | Fidelity Series Total Market Index | 1 year ago | 22361 |
| 9. | Northern Trust Extended Eq Market Idx | 1 year ago | 19827 |
| 10. | NT Ext Equity Mkt Idx Fd - L | 1 year ago | 19827 |
| 11. | NT Ext Equity Mkt Idx Fd - NL | 1 year ago | 18186 |
| 12. | Fidelity Nasdaq Composite Index | 1 year ago | 16704 |
| 13. | Vanguard U.S. Eq Idx £ Acc | 1 year ago | 15674 |
| 14. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 1 year ago | 14606 |
| 15. | Spartan Extended Market Index Pool E | 1 year ago | 10217 |
| 16. | Spartan Total Market Index Pool E | 1 year ago | 9654 |
| 17. | Schwab Total Stock Market Index | 1 year ago | 6977 |
| 18. | Extended Equity Market Fund M | 1 year ago | 6876 |
| 19. | SSgA U.S. Extended Market Index Class I | 1 year ago | 2800 |
| 20. | State St US Extended Mkt Indx NL Cl C | 1 year ago | 2800 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vivo Capital, LLC | 1 year ago | 1666746 |
| 2. | Bvf Inc | 1 year ago | 1202067 |
| 3. | AIGH Capital Management, LLC | 1 year ago | 1182198 |
| 4. | Rosalind Advisors, Inc. | 1 year ago | 1038828 |
| 5. | Vanguard Group Inc | 1 year ago | 683686 |
| 6. | Worth Venture Partners, LLC | 1 year ago | 294248 |
| 7. | CIBC World Markets Inc. | 1 year ago | 261429 |
| 8. | ADAR1 Capital Management LLC | 1 year ago | 231302 |
| 9. | Geode Capital Management, LLC | 1 year ago | 169602 |
| 10. | Hunting Hill Global Capital, LLC | 1 year ago | 104398 |
| 11. | BlackRock Inc | 1 year ago | 91932 |
| 12. | Marshall Wace Asset Management Ltd | 1 year ago | 86665 |
| 13. | Morgan Stanley - Brokerage Accounts | 1 year ago | 82994 |
| 14. | State Street Corporation | 1 year ago | 68757 |
| 15. | Northern Trust Corp | 1 year ago | 60667 |
| 16. | Easterly Investment Partners. | 1 year ago | 54969 |
| 17. | Millennium Management LLC | 1 year ago | 36726 |
| 18. | Group One Trading, LP | 1 year ago | 18240 |
| 19. | WealthPlan Investment Management, LLC | 1 year ago | 17443 |
| 20. | Wolverine Trading LLC | 1 year ago | 13403 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...